Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Challenges in Managing Patients with Hereditary Cancer at Gynecological Services.

Ueda M, Tsubamoto H, Kashima-Morii M, Torii Y, Kamihigashi M, Wakimoto Y, Nakagomi N, Hashimoto-Tamaoki T, Sawai H, Shibahara H.

Obstet Gynecol Int. 2019 May 27;2019:4365754. doi: 10.1155/2019/4365754. eCollection 2019.

2.

The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.

Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ.

BMC Cancer. 2016 Jan 14;16:18. doi: 10.1186/s12885-015-2011-5. Review.

3.

[Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].

Arai M, Iwase T, Takazawa Y, Takeshima N.

Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9. Review. Japanese.

PMID:
25434434
5.

Clinical background and outcomes of risk-reducing salpingo-oophorectomy for hereditary breast and ovarian cancers in Japan.

Nomura H, Sekine M, Yokoyama S, Arai M, Enomoto T, Takeshima N, Nakamura S.

Int J Clin Oncol. 2019 Sep;24(9):1105-1110. doi: 10.1007/s10147-019-01456-4. Epub 2019 May 4.

PMID:
31055694
6.

Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.

Adachi M, Banno K, Yanokura M, Iida M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Ueki A, Hirasawa A, Tominaga E, Aoki D.

Mol Clin Oncol. 2015 Mar;3(2):267-273. Epub 2014 Nov 20.

7.

Early-onset primary peritoneal carcinoma from atypical cells after risk-reducing salpingo-oophorectomy for BRCA2 mutation carrier: a case report.

Shimizu H, Ishikawa T, Iitsuka C, Homma M, Takimoto M, Sekizawa A.

Int Cancer Conf J. 2017 Mar 21;6(3):104-108. doi: 10.1007/s13691-017-0287-9. eCollection 2017 Jul.

8.

[Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].

Arai M, Taki K, Iwase H, Takizawa K, Nishimura S, Iwase T.

Gan To Kagaku Ryoho. 2012 Apr;39(4):525-31. Japanese.

PMID:
22504676
9.

Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year experience and reappraisal of its clinical utility.

Landon G, Stewart J, Deavers M, Lu K, Sneige N.

Gynecol Oncol. 2012 Jun;125(3):683-6. doi: 10.1016/j.ygyno.2012.03.009. Epub 2012 Mar 13.

10.

The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.

Miller H, Pipkin LS, Tung C, Hall TR, Masand RP, Anderson ML.

J Minim Invasive Gynecol. 2017 Jul - Aug;24(5):772-776. doi: 10.1016/j.jmig.2017.03.001. Epub 2017 Mar 8.

PMID:
28285055
11.

The gynecological surveillance of women with Lynch syndrome in Sweden.

Tzortzatos G, Andersson E, Soller M, Askmalm MS, Zagoras T, Georgii-Hemming P, Lindblom A, Tham E, Mints M.

Gynecol Oncol. 2015 Sep;138(3):717-22. doi: 10.1016/j.ygyno.2015.07.016. Epub 2015 Jul 12.

PMID:
26177554
12.
13.

[Clinical Management of HBOC in Our Hospital].

Nomura H, Takeshima N.

Gan To Kagaku Ryoho. 2017 Feb;44(2):116-120. Japanese.

PMID:
28223670
14.

Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.

Ricciardi E, Tomao F, Aletti G, Bazzurini L, Bocciolone L, Boveri S, Landoni F, Lapresa MT, Maruccio M, Parma G, Peccatori F, Petrella MC, Zanagnolo V, Colombo N, Maggioni A.

Anticancer Res. 2017 Sep;37(9):5241-5248.

PMID:
28870960
15.

Do hereditary syndrome-related gynecologic cancers have any specific features?

Neto N, Cunha TM.

Insights Imaging. 2015 Oct;6(5):545-52. doi: 10.1007/s13244-015-0425-x. Epub 2015 Sep 4.

16.

Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.

Casey MJ, Bewtra C, Lynch HT, Snyder C, Stacy M, Watson P.

Fam Cancer. 2013 Dec;12(4):719-40. doi: 10.1007/s10689-013-9651-x.

PMID:
23666231
17.

Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy.

Menkiszak J, Chudecka-Głaz A, Cymbaluk-Płoska A, Celewicz A, Kojs Z, Szajda M, Świniarska M, Bedner R, Jurczak A, Celewicz M, Cieszyńska M, Lubiński J, Gronwald J.

Hered Cancer Clin Pract. 2019 Mar 14;17:10. doi: 10.1186/s13053-019-0109-5. eCollection 2019.

18.

Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.

Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.

Am J Surg Pathol. 2009 Aug;33(8):1125-36. doi: 10.1097/PAS.0b013e31819e986a.

PMID:
19440148
19.

Hereditary non-BRCA gynecological tumors.

Vellone VG, Paudice M, Varesco L.

Minerva Ginecol. 2016 Oct;68(5):579-86. Epub 2016 Mar 1. Review.

PMID:
26930387
20.

Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.

Casey MJ, Bewtra C.

Fam Cancer. 2004;3(3-4):265-81. Review.

PMID:
15516851

Supplemental Content

Support Center